ROP · Roper Technologies Q2 FY2026 earnings call record财报电话会记录

“Total revenue grew 9%, organic revenue grew 5%, EBITDA grew 5%, and free cash flow grew 11%.”

“On the back of this quarter's performance, we're raising our full-year DEPS guidance for the second time this year to a range of $22.15-$22.30.”

“In addition, we're raising our full-year revenue growth outlook, with total revenue now expected to be north of 8% and organic growth expected to be in the 6% range.”

“Demand is strong, but these products are interactive, and in many cases, they change how customers do their work, so the pace of adoption is still developing.”

“Revenue of $2.1 billion was up 9%, with organic growth of 5% and acquisitions contributing three points.”

“We exited the second quarter at 3.4x net debt to EBITDA, up from 3.1x at the end of Q1, reflecting the capital deployed towards share repurchases in the quarter.”

“Revenue grew 8% in total, with organic revenue growth of 5%, slightly better than our expectations.”

“It gives pharmacists and technicians more capacity for quality assurance, clinical review, answering nurses' questions, supporting customers, and absorbing volume without proportional headcount.”

“We're also increasing our full-year total revenue growth guidance to north of 8%, with organic revenue growth expected to be in the 6% area.”

“Obviously, with the last 12 months or so, 12-18 months with the current share price level of Roper in the broader software sector, all of a sudden, buybacks became significantly more attractive.”

“I should also say, on the last question, we always look at the buyback of our own stock versus an acquisition with a risk premium.”

“Neil, I know you're addressing a lot of different markets, but I'm curious, in what of those markets do you think you have the earliest appetite or demand from customers for AI solutions?”